ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Erleada® improves survival without damaging quality of life in prostate cancer trial
May 31, 2021Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life. -
FDA Approves Erleada (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
September 23, 2019The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Erleada (apalutamide) for the treatment of patients with ...
Pharma Sources Insight January 2025
